$MBOT

3 theses

bullish 100%neutral 0%bearish 0%

Avg return (6m)

-25.9%

Win rate (6m)

0% (2 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 6m ago

$MBOTr/pennystocksStock Infobullish

u/Sea-While-2840 · 134d agono track record yet

Why $MBOT is about to explode.. A whole new class of medical robots at an absolute steal!

MBOT's LIBERTY system is the first miniaturized, disposable endovascular robotic platform with flawless clinical data (100% success, 0% adverse effects) and a recurring razor-and-blade revenue model. The market is severely underpricing this innovation at ~$1.87, especially given massive TAM expansion potential beyond current vascular procedures into cancer screening.

At post $1.86Now $1.09-41.4% since posted6m ago

1d—

3d—

1w-4.8%

1m-5.9%

3m-22.6%

6m—

1y—

original post →

$MBOTr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/CanadianAbroad7 · 248d agono track record yet

Huge news for Microbot Medical ($MBOT) ahead of full commercial rollout

Microbot Medical's LIBERTY robotic system is gaining institutional validation with major hospital adoptions (Tampa General, Emory) ahead of full commercial rollout in April. The system addresses a 2.5 million-procedure annual market as the only FDA-cleared single-use endovascular robotic solution, positioning MBOT to capitalize on growing post-approval momentum.

At post $2.54Now $1.09-57.1% since posted6m ago

1d+2.0%

3d-5.1%

1w-5.9%

1m+3.1%

3m-32.7%

6m-40.9%

1y—

original post →

$MBOTr/pennystocksStock Infobullish

u/Southern_Two_8108 · 290d ago2 prior · 33% at 3mo

Why I think $MBOT is the most undervalued, overlooked, multi-bagger around.

Microbot Medical is undervalued due to FDA clearance of its LIBERTY endovascular robotic system, early hospital adoption, and clear 2026 commercialization catalysts including full market release and geographic expansion. Clinical data shows strong efficacy (100% robotic navigation success, 92% radiation exposure reduction), and the company targets a 2.5 million annual procedure market with secured manufacturing capital and growing investor visibility.

At post $2.12Now $1.09-48.6% since posted6m ago

1d+1.9%

3d+1.4%

1w-1.9%

1m-1.4%

3m+10.8%

6m-10.8%

1y—

original post →

End of results.